FDA Grants Priority Review to Genentech’s Emicizumab for Hemophilia A with Inhibitors

– Application based on positive results of Phase III study in adults
and adolescents with hemophilia A with inhibitors and interim Phase III
results in children –
Genentech, a member of the Roche Group (SIX: RO, ROG; OTC...

More From BioPortfolio on "FDA Grants Priority Review to Genentech’s Emicizumab for Hemophilia A with Inhibitors"

Relevant Topics

Clincial TrialsIn a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

PediatricsPediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...